Parkinson’s Disease – Updates in Diagnosis and Patient Management

Overview

Provider Statement

This continuing education activity is provided by

Support Statement

This activity is supported by an educational grant from AbbVie Inc.

Activity Description

Parkinson's disease is a neurodegenerative disorder, second only in prevalence to Alzheimer’s disease. Numerous therapeutic options, including carbidopa/levodopa, monoamine oxidase-B inhibitors, dopamine agonists, and device-assisted therapies, are available for treatment. These treatments are indicated at different stages following diagnosis. However, Parkinson’s disease progresses at highly variable rates, and no biomarkers, laboratory tests, or gold standard indexes are available to determine which stage a patient is experiencing. Therefore, accurately monitoring disease progression and selecting therapies appropriate to each stage of Parkinson’s disease presents a significant and clinically important challenge. Many practitioners are likely unaware of therapeutic agents under development that may improve care for patients with Parkinson’s disease. Due to the complexity of the disease, the many current and emerging choices for treatment, as well as the varied experience of each patient, Parkinson’s disease requires that clinicians provide a patient-centered approach that factors each patient’s unique experiences, perceptions, and priorities into the treatment decisions. In this educational activity, expert faculty will evaluate the criteria and tools for the timely identification of advancing motor and nonmotor symptoms in patients with Parkinson’s disease, assess current and emerging therapies for each stage of disease progression, and explore the rationale for patient-centered care in this setting.

Target Audience

The intended audience for this activity is neurologists and other healthcare professionals involved in the management of patients with Parkinson’s disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Assess available criteria and tools for the timely identification of advancing motor and nonmotor symptoms in patients with Parkinson’s disease.
• Evaluate current and emerging therapies for each stage of progression in patients with Parkinson’s disease.
• Explain the rationale for patient-centered care in the context of Parkinson’s disease.

Activity Chair

Rajesh Pahwa, MD
Laverne & Joyce Rider Professor of Neurology
Chief, Parkinson & Movement Disorders Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, KS

Faculty

Melissa Armstrong, MD, MSc, FAAN
Associate Professor & Associate Chair of Faculty Development
University of Florida Department of Neurology
Director, UF Health Dorothy Mangurian Clinical-Research Headquarters for Lewy Body Dementia
Normal Fixel Institute for Neurological Diseases
University of Florida
Gainesville, FL

Stuart Isaacson, MD
Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton
Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Boca Raton, FL

David G. Standaert, MD, PhD
John N. Whitaker Professor & Chair of Neurology
Heersink School of Medicine
University of Alabama at Birmingham
Birmingham, AL

Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, May 30, 2023, to May 29, 2024.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 6 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationship(s)

Melissa Armstrong, MD, MSc, FAAN
No relevant financial relationships to disclose.

Stuart Isaacson, MD
Consultant: AbbVie, Acadia, Acorda, Adamas, Alexza, Amneal, Cala, Cerevel, Enterin, Kyowa Kirin, Merz, Neurocrine, NeuroDerm, Pharma Two B, Roche, Scion NeuroStim, Stoparkinson, Supernus, Teva
Speaker Contracted by Ineligible Company: AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Neurocrine, Sunovion, Supernus, Teva
Independent Research Contractor: AbbVie, Biogen, BioVie, Cala, Cerevel, Enterin, Jazz, Lundbeck, Michael J. Fox Foundation, Neurocrine, NeuroDerm, Novartis, Parkinson Study Group, Pharma Two B, Praxis, Revance, Roche, Sage, Scion NeuroStim, Stoparkinson, Sun, Sunovion, Supernus, Teva, Theravance, Transposon, UCB

Rajesh Pahwa, MD
Consultant: Abbott, AbbVie, Acadia, Acorda, Allevion, Amneal, Artemida, BioVie, Cala, Convatec, Global Kinetics, Inbeeo, Insightec, Jazz, Kyowa Kirin, Lundbeck, Merz, Neurocrine, NeuroDerm, Ono, PhotoPharmics, Sage, Sunovion, Supernus, UCB, Wren
Independent Research Contractor: Abbott, AbbVie, Alexza, Annovis, Biogen, BlueRock, Bukwang, Cerevel, Global Kinetics, Jazz, Michael J. Fox Foundation, Neuraly, NeuroDerm, Parkinson’s Foundation, Praxis, Roche, Sage, Scion, Sun, UCB, Voyager

David G. Standaert, MD, PhD
Consultant: AbbVie, Alnylam, Appello, BlueRock, Coave Therapeutics, Curium Pharma, Roche, Sanofi-Aventis, Theravance
Independent Research Contractor: AbbVie, Roche

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at cme@vindicoCME.com